HOME >> BIOLOGY >> NEWS
Drug lowers inflammatory markers associated with risk for heart attack

The trial included MI patients who carry at-risk variants in the FLAP gene or in the leukotriene A4 hydrolase gene. Of 268 patients screened, 191 were carriers of at-risk variants in FLAP (87 percent) or leukotriene A4 hydrolase (13 percent). Individuals were enrolled in April 2004 and were followed up by designated cardiologists from the Landspitali University Hospital in Iceland until September 2004. Patients were first randomized to receive 250 mg/d of DG-031, 500 mg/d of DG-031, 750 mg/d of DG-031, or placebo. After a 2-week washout period, patients received DG-031 if they had received placebo first or placebo if they had received DG-031 first. Treatment periods lasted for 4 weeks.

The researchers found that levels of several biomarkers linked to arterial inflammation and risk of MI decreased. In response to 750 mg/d of DG-031, production of leukotriene B4 was significantly reduced by 26 percent and myeloperoxidase was significantly reduced by 12 percent. The higher 2 doses of DG-031 produced a nonsignificant reduction in C-reactive protein (16 percent) at 2 weeks. However, there was a more pronounced reduction (25 percent) in C-reactive protein at the end of the washout period that was significant and persisted for another 4 weeks thereafter. An 8-day, open-label follow-up study with 75 patients with the same genetic and disease profile as in the Phase IIa was conducted to further examine the effect of DG031 on CRP and myeloperoxidase. The results of this study showed that the 750mg/d dose of DG031, when administered as 250 mg 3 times daily resulted in a 38 percent reduction in CRP levels, as well as a 31 percent reduction in myeloperoxidase levels measured 6 hours after dosing on day 8. In both studies, the FLAP inhibitor DG-031 was well-tolerated and was not associated with any serious adverse events.

"When taken together, the data from our MI gene-isolation study and the clinical trial reported herein show that DG-031 is a safe and w
'"/>

Contact: Edward Farmer
edward.farmer@decode.is
354-570-2819
JAMA and Archives Journals
10-May-2005


Page: 1 2 3 4

Related biology news :

1. Columbine flowers develop long nectar spurs in response to pollinators
2. Nondanger signal lowers immune reactions
3. Plants with male and bisexual flowers on the same plant are better mothers
4. Flowers shape themselves to guide their pollinators to the pollen
5. Orange juice beverage fortified with plant sterols lowers indicators of heart disease risk
6. How did bilaterally symmetric flowers evolve from radially symmetric ones?
7. Genetic snooze button governs timing of spring flowers
8. Wild bees and the flowers they pollinate are disappearing together
9. Low-to-moderate prenatal alcohol exposure lowers IQ at age 10
10. How flowers changed the world a new book by Field Museum scientist
11. Lots of flowers and trees, not enough birds and bees

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced it has issued a scientific white paper entitled “Results from ... series of commentaries from ProMIS’s scientific team offering insight into the Company’s product ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... productivity traits and nutritional products, today announced their collaboration to achieve ... China to the United States ... ...
(Date:2/22/2017)... and SAN DIEGO , Feb. ... "Company") (OTCQB:CELZ) announced today expansion of its translational ... cell product through establishment of laboratory facilities in ... at the San Diego BioLabs facility, a biotechnology ... Novartis, and Sanofi. In November 2016, ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, ... health applications, announced a partnership with Redox, a leader in cloud-based healthcare integration ... clinical systems while keeping data secure in the cloud. , The digital health ...
Breaking Biology Technology:
Cached News: